Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: An asian perspective

Molecules

Volumn 20, Issue 4, 2015, Pages 6068-6092

  Miftahussurur, Muhammad ^a,b   Yamaoka, Yoshio ^a,c  

^a OITA UNIVERSITY   (Japan)

^b AIRLANGGA UNIVERSITY   (Indonesia)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Amoxicillin (AMX); Antibiotic resistance; Asia; Clarithromycin (CAM); CYP2C19 polymorphisms; Helicobacter pylori; Metronidazole (MNZ); Proton pump inhibitor (PPI)

Indexed keywords

ANTIINFECTIVE AGENT; CYTOCHROME P450 2C19; PROTON PUMP INHIBITOR;

ANTIBIOTIC RESISTANCE; ASIA; COMPLICATION; DRUG EFFECTS; GENETICS; HEALTH CARE QUALITY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMAN; MICROBIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH NEOPLASMS;

ANTI-BACTERIAL AGENTS; ASIA; CYTOCHROME P-450 CYP2C19; DRUG RESISTANCE, BACTERIAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTON PUMP INHIBITORS; STANDARD OF CARE; STOMACH NEOPLASMS;

EID: 84928721223     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules20046068     Document Type: Review

References (129)

1. Suerbaum, S.; Michetti, P. Helicobacter pylori infection. N. Engl. J. Med. 2002, 347, 1175-1186.
2. Correa, P. Human gastric carcinogenesis: A multistep and multifactorial process - First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992, 52, 6735-6740.
3. Thirumurthi, S.; Graham, D.Y. Helicobacter pylori infection in India from a western perspective. Indian J. Med. Res. 2012, 136, 549-562.
4. Fock, K.M.; Ang, T.L. Epidemiology of Helicobacter pylori infection and gastric cancer in Asia. J. Gastroenterol. Hepatol. 2010, 25, 479-486.
5. Wang, K.J.; Wang, R.T. Meta-analysis on the epidemiology of Helicobacter pylori infection in China. Zhonghua Liu Xing Bing Xue Za Zhi 2003, 24, 443-446.
6. Fujisawa, T.; Kumagai, T.; Akamatsu, T.; Kiyosawa, K.; Matsunaga, Y. Changes in seroepidemiological pattern of Helicobacter pylori and hepatitis A virus over the last 20 years in Japan. Am. J. Gastroenterol. 1999, 94, 2094-2099.
7. Yim, J.Y.; Kim, N.; Choi, S.H.; Kim, Y.S.; Cho, K.R.; Kim, S.S.; Seo, G.S.; Kim, H.U.; Baik, G.H.; Sin, C.S.; et al. Seroprevalence of Helicobacter pylori in South Korea. Helicobacter 2007, 12, 333-340.
8. Hoang, T.T.; Bengtsson, C.; Phung, D.C.; Sörberg, M.; Granström, M. Seroprevalence of Helicobacter pylori infection in urban and rural Vietnam. Clin. Diagn. Lab. Immunol. 2005, 12, 81-85.
9. Nurgalieva, Z.Z.; Malaty, H.M.; Graham, D.Y.; Almuchambetova, R.; Machmudova, A.; Kapsultanova, D.; Osato, M.S.; Hollinger, F.B.; Zhangabylov, A. Helicobacter pylori infection in Kazakhstan: Effect of water source and household hygiene. Am. J. Trop. Med. Hyg. 2002, 67, 201-206.
10. Novis, B.H.; Gabay, G.; Naftali, T. Helicobacter pylori: The Middle East scenario. Yale J. Biol. Med. 1998, 71, 135-141.
11. Shokrzadeh, L.; Baghaei, K.; Yamaoka, Y.; Dabiri, H.; Jafari, F.; Sahebekhtiari, N.; Tahami, A.; Sugimoto, M.; Zojaji, H.; Zali, M.R. Analysis of 3′-end variable region of the cagA gene in Helicobacter pylori isolated from Iranian population. J. Gastroenterol. Hepatol. 2010, 25, 172-177.
12. Vilaichone, R.K.; Mahachai, V.; Shiota, S.; Uchida, T.; Ratanachu-ek, T.; Tshering, L.; Tung, N.L.; Fujioka, T.; Moriyama, M.; Yamaoka, Y. Extremely high prevalence of Helicobacter pylori infection in Bhutan. World J. Gastroenterol. 2013, 19, 2806-2810.
13. Miwa, H.; Go, M.F.; Sato, N. H. pylori and gastric cancer: The Asian enigma. Am. J. Gastroenterol. 2002, 97, 1106-1112.
14. Bani-Hani, K.E.; Hammouri, S.M. Prevalence of Helicobacter pylori in Northern Jordan. Endoscopy based study. Saudi Med. J. 2001, 22, 843-847.
15. Bener, A.; Uduman, S.A.; Ameen, A.; Alwash, R.; Pasha, M.A.; Usmani, M.A.; AI-Naili, S.R.; Amiri, K.M. Prevalence of Helicobacter pylori infection among low socio-economic workers. J. Commun. Dis. 2002, 34, 179-184.
16. Miftahussurur, M.; Shiota, S.; Suzuki, R.; Matsuda, M.; Uchida, T.; Kido, Y.; Kawamoto, F.; Maimunah, U.; Adi, P.; Rezkitha, Y.; et al. Identification of Helicobacter pylori infection in symptomatic patients in Surabaya, Indonesia, using five diagnostic tests. Epidemiol. Infect. 2014, 143, 986-996.
17. Graham, D.Y.; Fischbach, L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010, 59, 1143-1153.
18. Kuo, C.H.; Kuo, F.C.; Hu, H.M.; Liu, C.J.; Wang, S.S.; Chen, Y.H.; Hsieh, M.C.; Hou, M.F.; Wu, D.C. The Optimal First-Line Therapy of Helicobacter pylori Infection in Year 2012. Gastroenterol. Res. Pract. 2012, doi:10.1155/2012/168361.
19. Papastergiou, V.; Georgopoulos, S.D.; Karatapanis, S. Treatment of Helicobacter pylori infection: Meeting the challenge of antimicrobial resistance. World J. Gastroenterol. 2014, 20, 9898-9911.
20. Megraud, F. H pylori antibiotic resistance: Prevalence, importance, and advances in testing. Gut 2004, 53, 1374-1384.
21. Megraud, F. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology 1998, 115, 1278-1282.
22. Broutet, N.; Tchamgoue, S.; Pereira, E.; Lamouliatte, H.; Salamon, R.; Megraud, F. Risk factors for failure of Helicobacter pylori therapy - Results of an individual data analysis of 2751 patients. Aliment. Pharmacol. Ther. 2003, 17, 99-109.
23. Megraud, F.; Lehours, P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin. Microbiol. Rev. 2007, 20, 280-322.
24. Ierardi, E.; Giorgio, F.; Losurdo, G.; di Leo, A. Principi M: How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography? World J. Gastroenterol. 2013, 19, 8168-8180.
25. De Francesco, V.; Margiotta, M.; Zullo, A.; Hassan, C.; Troiani, L.; Burattini, O.; Stella, F.; di Leo, A.; Russo, F.; Marangi, S.; et al. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann. Intern. Med. 2006, 144, 94-100.
26. Oleastro, M.; Ménard, A.; Santos, A.; Lamouliatte, H.; Monteiro, L.; Barthélémy, P.; Mégraud, F. Real-time PCR assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in Helicobacter pylori. J. Clin. Microbiol. 2003, 41, 397-402.
27. Kobayashi, I.; Murakami, K.; Kato, M.; Kato, S.; Azuma, T.; Takahashi, S.; Uemura, N.; Katsuyama, T.; Fukuda, Y.; Haruma, K.; et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J. Clin. Microbiol. 2007, 45, 4006-4010.
28. Lee, J.W.; Kim, N.; Kim, J.M.; Nam, R.H.; Chang, H.; Kim, J.Y.; Shin, C.M.; Park, Y.S.; Lee, D.H.; Jung, H.C. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter 2013, 18, 206-214.
29. Gao, W.; Cheng, H.; Hu, F.; Li, J.; Wang, L.; Yang, G.; Xu, L.; Zheng, X. The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing, China. Helicobacter 2010, 15, 460-466.
30. Khan, A.; Farooqui, A.; Manzoor, H.; Akhtar, S.S.; Quraishy, M.S.; Kazmi, S.U. Antibiotic resistance and cagA gene correlation: A looming crisis of Helicobacter pylori. World J. Gastroenterol. 2012, 18, 2245-2252.
31. Pandya, H.B.; Agravat, H.H.; Patel, J.S.; Sodagar, N. Emerging antimicrobial resistance pattern of Helicobacter pylori in central Gujarat. Indian J. Med. Microbiol. 2014, 32, 408-413.
32. Fakheri, H.; Bari, Z.; Aarabi, M.; Malekzadeh, R. Helicobacter pylori eradication in West Asia: A review. World J. Gastroenterol. 2014, 20, 10355-10367.
33. Safaralizadeh, R.; Siavoshi, F.; Malekzadeh, R.; Akbari, M.R.; Derakhshan, M.H.; Sohrabi, M.R.; Massarrat, S. Antimicrobial effectiveness of furazolidone against metronidazole-resistant strains of Helicobacter pylori. East Mediterr. Health J. 2006, 12, 286-293.
34. Ozbey, G.; Bahcecioglu, I.H.; Acik, M.N. Resistance rates to various antimicrobial agents of Helicobacter pylori isolates in Eastern Turkey. Int. J. Mol. Clin. Microbiol. 2012, 2, 148-152.
35. Bindayna, K.M. Antibiotic susceptibilities of Helicobacter pylori. Saudi Med. J. 2001, 22, 53-57.
36. Binh, T.T.; Shiota, S.; Nguyen, L.T.; Ho, D.D.; Hoang, H.H.; Ta, L.; Trinh, D.T.; Fujioka, T.; Yamaoka, Y. The incidence of primary antibiotic resistance of Helicobacter pylori in Vietnam. J. Clin. Gastroenterol. 2013, 47, 233-238.
37. Kumala, W.; Rani, A. Patterns of Helicobacter pylori isolate resistance to fluoroquinolones, amoxicillin, clarithromycin and metronidazoles. Southeast Asian J. Trop. Med. Public Health 2006, 37, 970-974.
38. Vilaichone, R.K.; Gumnarai, P.; Ratanachu-Ek, T.; Mahachai, V. Nationwide survey of Helicobacter pylori antibiotic resistance in Thailand. Diagn Microbiol. Infect Dis. 2013, 77, 346-349.
39. Hua, J.S.; Bow, H.; Zheng, P.Y.; Khay-Guan, Y. Prevalence of primary Helicobacter pylori resistance to metronidazole and clarithromycin in Singapore. World J. Gastroenterol. 2000, 6, 119-121.
40. Vilaichone, R.K.; Yamaoka, Y.; Shiota, S.; Ratanachu-ek, T.; Tshering, L.; Uchida, T.; Fujioka, T.; Mahachai, V. Antibiotics resistance rate of Helicobacter pylori in Bhutan. World J. Gastroenterol. 2013, 19, 5508-5512.
41. Goh, K.L.; Navaratnam, P. High Helicobacter pylori resistance to metronidazole but zero or low resistance to clarithromycin, levofloxacin, and other antibiotics in Malaysia. Helicobacter 2011, 16, 241-245.
42. Gerrits, M.M.; van der Wouden, E.J.; Bax, D.A.; van Zwet, A.A.; van Vliet, A.H.; de Jong, A.; Kusters, J.G.; Thijs, J.C.; Kuipers, E.J. Role of the rdxA and frxA genes in oxygen-dependent metronidazole resistance of Helicobacter pylori. J. Med. Microbiol. 2004, 53, 1123-1128.
43. Bereswill, S.; Krainick, C.; Stahler, F.; Herrmann, L.; Kist, M. Analysis of the rdxA gene in high-level metronidazole-resistant clinical isolates confirms a limited use of rdxA mutations as a marker for prediction of metronidazole resistance in Helicobacter pylori. FEMS Immunol. Med. Microbiol. 2003, 36, 193-198.
44. Su, P.; Li, Y.; Li, H.; Zhang, J.; Lin, L.; Wang, Q.; Guo, F.; Ji, Z.; Mao, J.; Tang, W.; et al. Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China. Helicobacter 2013, 18, 274-279.
45. Goh, K.L.; Chan, W.K.; Shiota, S.; Yamaoka, Y. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter 2011, 16 (Suppl. 1), 1-9.
46. Kim, J.M.; Kim, J.S.; Kim, N.; Kim, S.G.; Jung, H.C.; Song, I.S. Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients. Int. J. Antimicrob. Agents 2006, 28, 6-13.
47. Wang, W.H.; Wong, B.C.; Mukhopadhyay, A.K.; Berg, D.E.; Cho, C.H.; Lai, K.C.; Hu, W.H.; Fung, F.M.; Hui, W.M.; Lam, S.K. High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. Aliment. Pharmacol. Ther. 2000, 14, 901-910.
48. Ahmad, N.; Zakaria, W.R.; Mohamed, R. Analysis of antibiotic susceptibility patterns of Helicobacter pylori isolates from Malaysia. Helicobacter 2011, 16, 47-51.
49. Binh, T.T.; Suzuki, R.; Shiota, S.; Kwon, D.H.; Yamaoka, Y. Complete Genome Sequences of Helicobacter pylori Clarithromycin-Resistant Strains. Genome Announc. 2013, doi:10.1128/genomeA.00912-13.
50. Abadi, A.T.; Taghvaei, T.; Mobarez, A.M.; Carpenter, B.M.; Merrell, D.S. Frequency of antibiotic resistance in Helicobacter pylori strains isolated from the northern population of Iran. J. Microbiol. 2011, 49, 987-993.
51. Eltahawy, A.T. Prevalence of primary Helicobacter pylori resistance to several antimicrobials in a Saudi Teaching Hospital. Med. Princ. Pract. 2002, 11, 65-68.
52. Horiki, N.; Omata, F.; Uemura, M.; Suzuki, S.; Ishii, N.; Iizuka, Y.; Fukuda, K.; Fujita, Y.; Katsurahara, M.; Ito, T.; et al. Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan. Helicobacter 2009, 14, 86-90.
53. Poon, S.K.; Lai, C.H.; Chang, C.S.; Lin, W.Y.; Chang, Y.C.; Wang, H.J.; Lin, P.H.; Lin, H.J.; Wang, W.C. Prevalence of antimicrobial resistance in Helicobacter pylori isolates in Taiwan in relation to consumption of antimicrobial agents. Int. J. Antimicrob. Agents 2009, 34, 162-165.
54. Hu, C.T.; Wu, C.C.; Lin, C.Y.; Cheng, C.C.; Su, S.C.; Tseng, Y.H.; Lin, N.T. Resistance rate to antibiotics of Helicobacter pylori isolates in eastern Taiwan. J. Gastroenterol. Hepatol. 2007, 22, 720-723.
55. Farshad, S.; Alborzi, A.; Japoni, A.; Ranjbar, R.; Hosseini Asl, K.; Badiee, P.; Amin Shahidi, M.; Hosseini, M. Antimicrobial susceptibility of Helicobacter pylori strains isolated from patients in Shiraz, Southern Iran. World J. Gastroenterol. 2010, 16, 5746-5751.
56. Thyagarajan, S.P.; Ray, P.; Das, B.K.; Ayyagari, A.; Khan, A.A.; Dharmalingam, S.; Rao, U.A.; Rajasambandam, P.; Ramathilagam, B.; Bhasin, D.; et al. Geographical difference in antimicrobial resistance pattern of Helicobacter pylori clinical isolates from Indian patients: Multicentric study. J. Gastroenterol. Hepatol. 2003, 18, 1373-1378.
57. Shiota, S.; Suzuki, R.; Yamaoka, Y. The significance of virulence factors in Helicobacter pylori. J. Dig. Dis. 2013, 14, 341-349.
58. Hachem, C.Y.; Clarridge, J.E.; Reddy, R.; Flamm, R.; Evans, D.G.; Tanaka, S.K.; Graham, D.Y. Antimicrobial susceptibility testing of Helicobacter pylori. Comparison of E-test, broth microdilution, and disk diffusion for ampicillin, clarithromycin, and metronidazole. Diagn. Microbiol. Infect. Dis. 1996, 24, 37-41.
59. Glupczynski, Y.; Labbe, M.; Hansen, W.; Crokaert, F.; Yourassowsky, E. Evaluation of the E test for quantitative antimicrobial susceptibility testing of Helicobacter pylori. J. Clin. Microbiol. 1991, 29, 2072-2075.
60. Chaves, S.; Gadanho, M.; Tenreiro, R.; Cabrita, J. Assessment of metronidazole susceptibility in Helicobacter pylori: Statistical validation and error rate analysis of breakpoints determined by the disk diffusion test. J. Clin. Microbiol. 1999, 37, 1628-1631.
61. DeCross, A.J.; Marshall, B.J.; McCallum, R.W.; Hoffman, S.R.; Barrett, L.J.; Guerrant, R.L. Metronidazole susceptibility testing for Helicobacter pylori: Comparison of disk, broth, and agar dilution methods and their clinical relevance. J. Clin. Microbiol. 1993, 31, 1971-1974.
62. Cederbrant, G.; Kahlmeter, G.; Ljungh, A. The E test for antimicrobial susceptibility testing of Helicobacter pylori. J. Antimicrob. Chemother. 1993, 31, 65-71.
63. Fock, K.M.; Katelaris, P.; Sugano, K.; Ang, T.L.; Hunt, R.; Talley, N.J.; Lam, S.K.; Xiao, S.D.; Tan, H.J.; Wu, C.Y.; et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J. Gastroenterol. Hepatol. 2009, 24, 1587-1600.
64. Kim, S.G.; Jung, H.K.; Lee, H.L.; Jang, J.Y.; Lee, H.; Kim, C.G.; Shin, W.G.; Shin, E.S.; Lee, Y.C.; Korean College of Helicobacter and Upper Gastrointestinal Research. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. Korean J. Gastroenterol. 2013, 62, 3-26.
65. Asaka, M. A new approach for elimination of gastric cancer deaths in Japan. Int. J. Cancer 2013, 132, 1272-1276.
66. Chinese Society of Gastroenterology, Chinese Study Group on Helicobacter pylori1; Liu, W.Z.; Xie, Y.; Cheng, H.; Lu, N.H.; Hu, F.L.; Zhang, W.D.; Zhou, L.Y.; Chen, Y.; Zeng, Z.R.; Wang, C.W.; et al. Fourth Chinese National Consensus Report on the management of Helicobacter pylori infection. J. Dig. Dis. 2013, 14, 211-221.
67. Murakami, K.; Okimoto, T.; Kodama, M.; Sato, R.; Watanabe, K.; Fujioka, T. Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection. J. Clin. Gastroenterol. 2008, 42, 139-142.
68. Shimoyama, T.; Fukuda, S.; Mikami, T.; Fukushi, M.; Munakata, A. Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population. J. Gastroenterol. 2004, 39, 927-930.
69. Gong, E.J.; Yun, S.C.; Jung, H.Y.; Lim, H.; Choi, K.S.; Ahn, J.Y.; Lee, J.H.; Kim, D.H.; Choi, K.D.; Song, H.J.; et al. Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: Is it time to change? J. Korean Med. Sci. 2014, 29, 704-713.
70. Gopal, R.; Elamurugan, T.P.; Kate, V.; Jagdish, S.; Basu, D. Standard triple versus levofloxacin based regimen for eradication of Helicobacter pylori. World J. Gastrointest. Pharmacol. Ther. 2013, 4, 23-27.
71. Nguyen, T.V.; Bengtsson, C.; Nguyen, G.K.; Hoang, T.T.; Phung, D.C.; Sorberg, M.; Granstrom, M. Evaluation of two triple-therapy regimens with metronidazole or clarithromycin for the eradication of H. pylori infection in Vietnamese children: A randomized, double-blind clinical trial. Helicobacter 2008, 13, 550-556.
72. Malfertheiner, P.; Megraud, F.; O'Morain, C.; Bazzoli, F.; El-Omar, E.; Graham, D.; Hunt, R.; Rokkas, T.; Vakil, N.; Kuipers, E.J. Current concepts in the management of Helicobacter pylori infection: The Maastricht III Consensus Report. Gut 2007, 56, 772-781.
73. Mahachai, V.; Thong-Ngam, D.; Noophun, P.; Tumwasorn, S.; Kullavanijaya, P. Efficacy of clarithromycin-based triple therapy for treating Helicobacter pylori in Thai non-ulcer dyspeptic patients with clarithromycin-resistant strains. J. Med. Assoc. Thail. = Chotmaihet thangphaet 2006, 89 (Suppl. 3), S74-S78.
74. Prasertpetmanee, S.; Mahachai, V.; Vilaichone, R.K. Improved efficacy of proton pump inhibitor - amoxicillin - clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy. Helicobacter 2013, 18, 270-273.
75. Uthaisaengsook, W. Low dose, one-week triple therapy (lanzoprazole, amoxycillin, clarithromycin) for eradication of Helicobacter pylori infection. J. Med. Assoc. Thail. = Chotmaihet thangphaet 2003, 86, 599-602.
76. Goh, K.; Parasakthi, N.; Cheah, P.; Ranjeev, C.; Rosmawati, M.; Tan, Y.; Chin, S. Efficacy of a 1-week pantoprazole triple therapy in eradicating Helicobacter pylori in Asian patients. J. Gastroenterol. Hepatol. 2000, 15, 910-914.
77. Yuan, Y.; Ford, A.C.; Khan, K.J.; Gisbert, J.P.; Forman, D.; Leontiadis, G.I.; Tse, F.; Calvet, X.; Fallone, C.; Fischbach, L.; et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst. Rev. 2013, 12, doi:10.1002/14651858.CD008337.pub2.
78. Fischbach, LA.; van Zanten, S.; Dickason, J. Meta-analysis: The efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment. Pharmacol. Ther. 2004, 20, 1071-1082.
79. Kuo, C.H.; Hsu, P.I.; Kuo, F.C.; Wang, S.S.; Hu, H.M.; Liu, C.J.; Chuah, S.K.; Chen, Y.H.; Hsieh, M.C.; Wu, D.C.; et al. Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line Helicobacter pylori therapy: A randomized controlled trial. J. Antimicrob. Chemother. 2013, 68, 222-228.
80. Lu, H.; Zhang, W.; Graham, D.Y. Bismuth-containing quadruple therapy for Helicobacter pylori: Lessons from China. Eur. J. Gastroenterol. Hepatol. 2013, 25, 1134-1140.
81. Liang, X.; Xu, X.; Zheng, Q.; Zhang, W.; Sun, Q.; Liu, W.; Xiao, S.; Lu, H. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin. Gastroenterol. Hepatol. 2013, 11, doi:10.1016/j.cgh.2013.01.008.
82. Wang, Z.; Wu, S. Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: An open-label control study in Chinese patients. Singap. Med. J. 2012, 53, 273-276.
83. Kumar, D.; Ahuja, V.; Dhar, A.; Sharma, M.P. Randomized trial of a quadruple-drug regimen and a triple-drug regimen for eradication of Helicobacter pylori: Long-term follow-up study. Indian J. Gastroenterol. 2001, 20, 191-194.
84. Chey, W.D.; Wong, B.C. Practice Parameters Committee of the American College of G. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am. J. Gastroenterol. 2007, 102, 1808-1825.
85. Lee, B.H.; Kim, N.; Hwang, T.J.; Lee, S.H.; Park, Y.S.; Hwang, J.H.; Kim, J.W.; Jeong, S.H.; Lee, D.H.; Jung, H.C. et al. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: Effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter 2010, 15, 38-45.
86. Lee, S.K.; Lee, S.W.; Park, J.Y.; Kwon, B.S.; Kim, S.Y.; Hyun, J.J.; Kim, J.H.; Jung, S.W.; Koo, J.S.; Yim, H.J.; et al. Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: Repeated quadruple therapy as a third-line therapy. Helicobacter 2011, 16, 410-414.
87. Yang, J.C.; Lu, C.W.; Lin, C.J. Treatment of Helicobacter pylori infection: Current status and future concepts. World J. Gastroenterol. 2014, 20, 5283-5293.
88. Yanai, A.; Sakamoto, K.; Akanuma, M.; Ogura, K.; Maeda, S. Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized study in Japan. World J. Gastrointest. Pharmacol. Ther. 2012, 3, 1-6.
89. Gisbert, J.P.; Calvet, X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin. Exp. Gastroenterol. 2012, 5, 23-34.
90. Nagahara, A.; Miwa, H.; Ogawa, K.; Kurosawa, A.; Ohkura, R.; Iida, N.; Sato, N. Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy. Helicobacter 2000, 5, 88-93.
91. Nagahara, A.; Miwa, H.; Yamada, T.; Kurosawa, A.; Ohkura, R.; Sato, N. Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. Aliment. Pharmacol. Ther. 2001, 15, 417-421.
92. Kim, S.Y.; Lee, S.W.; Hyun, J.J.; Jung, S.W.; Koo, J.S.; Yim, H.J.; Park, J.J.; Chun, H.J.; Choi, J.H. Comparative study of Helicobacter pylori eradication rates with 5-day quadruple "concomitant" therapy and 7-day standard triple therapy. J. Clin. Gastroenterol. 2013, 47, 21-24.
93. Kwon, D.H.; El-Zaatari, F.A.; Kato, M.; Osato, M.S.; Reddy, R.; Yamaoka, Y.; Graham, D.Y. Analysis of rdxA and involvement of additional genes encoding NAD(P)H flavin oxidoreductase (FrxA) and ferredoxin-like protein (FdxB) in metronidazole resistance of Helicobacter pylori. Antimicrob. Agents Chemother. 2000, 44, 2133-2142.
94. Gatta, L.; Vakil, N.; Vaira, D.; Scarpignato, C. Global eradication rates for Helicobacter pylori infection: Systematic review and meta-analysis of sequential therapy. BMJ 2013, 347, doi:10.1136/bmj.f4587.
95. Kim, J.S.; Ji, J.S.; Choi, H.; Kim, J.H. Sequential therapy or triple therapy for Helicobacter pylori infection in Asians: Systematic review and meta-analysis. Clin. Res. Hepatol. Gastroenterol. 2014, 38, 118-125.
96. Liou, J.M.; Chen, C.C.; Chen, M.J.; Chen, C.C.; Chang, C.Y.; Fang, Y.J.; Lee, J.Y.; Hsu, S.J.; Luo, J.C.; Chang, W.H.; et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: A multicentre, open-label, randomised trial. Lancet 2013, 381, 205-213.
97. Zhou, L.; Zhang, J.; Chen, M.; Hou, X.; Li, Z.; Song, Z.; He, L.; Lin, S. A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: A randomized multicenter trial. Am. J. Gastroenterol. 2014, 109, 535-541.
98. Chung, J.W.; Ha, M.; Yun, S.C.; Kim, J.H.; Lee, J.J.; Kim, Y.J.; Kim, K.O.; Kwon, K.A.; Park, D.K.; Lee, D.H. Meta-analysis: Sequential therapy is superior to conventional therapy for Helicobacter pylori infection in Korea. Korean J. Gastroenterol. = Taehan Sohwagi Hakhoe chi 2013, 62, 267-271.
99. Javid, G.; Zargar, S.A.; Bhat, K.; Khan, B.A.; Yatoo, G.N.; Gulzar, G.M.; Shah, A.H.; Sodhi, J.S.; Khan, M.A.; Shoukat, A.; et al. Efficacy and safety of sequential therapy versus standard triple therapy in Helicobacter pylori eradication in Kashmir India: A randomized comparative trial. Indian J. Gastroenterol. 2013, 32, 190-194.
100. Sardarian, H.; Fakheri, H.; Hosseini, V.; Taghvaei, T.; Maleki, I.; Mokhtare, M. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: A prospective randomized trial. Helicobacter 2013, 18, 129-134.
101. Hsu, P.I.; Wu, D.C.; Wu, J.Y.; Graham, D.Y. Modified sequential Helicobacter pylori therapy: Proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter 2011, 16, 139-145.
102. Oh, D.H.; Lee, D.H.; Kang, K.K.; Park, Y.S.; Shin, C.M.; Kim, N.; Yoon, H.; Hwang, J.H.; Jeoung, S.H.; Kim, J.W.; et al. Efficacy of hybrid therapy as first-line regimen for Helicobacter pylori infection compared with sequential therapy. J. Gastroenterol. Hepatol. 2014, 29, 1171-1176.
103. Metanat, H.A.; Valizadeh, S.M.; Fakheri, H.; Maleki, I.; Taghvaei, T.; Hosseini, V.; Bari, Z. Comparison Between 10- and 14-Day Hybrid Regimens for Helicobacter pylori Eradication: A Randomized Clinical Trial. Helicobacter 2015, doi:10.1111/hel.12202, in press.
104. Rimbara, E.; Fischbach, L.A.; Graham, D.Y. Optimal therapy for Helicobacter pylori infections. Nat. Rev. Gastroenterol. Hepatol. 2011, 8, 79-88.
105. Sugimoto, M.; Furuta, T. Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. World J. Gastroenterol. 2014, 20, 6400-6411.
106. Liou, J.M.; Chen, C.C.; Chang, C.Y.; Chen, M.J.; Fang, Y.J.; Lee, J.Y.; Hsu, S.J.; Hsu, Y.C.; Tseng, C.H.; Tseng, P.H.; et al. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: A multicentre clinical trial. J. Antimicrob. Chemother. 2013, 68, 450-456.
107. Scott, D.; Weeks, D.; Melchers, K.; Sachs, G. The life and death of Helicobacter pylori. Gut 1998, 43 (Suppl. 1), S56-S60.
108. Figura, N.; Crabtree, J.E.; Dattilo, M. In-vitro activity of lansoprazole against Helicobacter pylori. J. Antimicrob. Chemother. 1997, 39, 585-590.
109. Erah, P.O.; Goddard, A.F.; Barrett, D.A.; Shaw, P.N.; Spiller, R.C. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: Relevance to the treatment of Helicobacter pylori infection. J. Antimicrob. Chemother. 1997, 39, 5-12.
110. Goddard, A.F.; Jessa, M.J.; Barrett, D.A.; Shaw, P.N.; Idstrom, J.P.; Cederberg, C.; Spiller, R.C. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 1996, 111, 358-367.
111. Kita, T.; Tanigawara, Y.; Aoyama, N.; Hohda, T.; Saijoh, Y.; Komada, F.; Sakaeda, T.; Okumura, K.; Sakai, T.; Kasuga, M. CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability. Pharm. Res. 2001, 18, 615-621.
112. Kawakami, Y.; Akahane, T.; Yamaguchi, M.; Oana, K.; Takahashi, Y.; Okimura, Y.; Okabe, T.; Gotoh, A.; Katsuyama, T. In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori. Antimicrob. Agents Chemother. 2000, 44, 458-461.
113. Wong, B.C.; Wong, W.M.; Yee, Y.K.; Hung, W.K.; Yip, A.W.; Szeto, M.L.; Li, K.F.; Lau, P.; Fung, F.M.; Tong, T.S.; et al. Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 2001, 15, 1959-1965.
114. Murakami, K.; Sato, R.; Okimoto, T.; Nasu, M.; Fujioka, T.; Kodama, M.; Kagawa, J.; Sato, S.; Abe, H.; Arita, T. Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Aliment. Pharmacol. Ther. 2002, 16, 1933-1938.
115. Kositchaiwat, C.; Ovartlarnporn, B.; Kachintorn, U.; Atisook, K. Low and high doses of rabeprazole vs. omeprazole for cure of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 2003, 18, 1017-1021.
116. McNicholl, A.G.; Linares, P.M.; Nyssen, O.P.; Calvet, X.; Gisbert, J.P. Meta-analysis: Esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 2012, 36, 414-425.
117. Maconi, G.; Parente, F.; Russo, A.; Vago, L.; Imbesi, V.; Bianchi Porro, G. Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? Am. J. Gastroenterol. 2001, 96, 359-366.
118. Fuccio, L.; Minardi, M.E.; Zagari, R.M.; Grilli, D.; Magrini, N.; Bazzoli, F. Meta-analysis: Duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann. Intern. Med. 2007, 147, 553-562.
119. Andersson, T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin. Pharmacokinet. 1996, 31, 9-28.
120. Meyer, U.A. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur. J. Gastroenterol. Hepatol. 1996, 8 (Suppl. 1), S21-S25.
121. VandenBranden, M.; Ring, B.J.; Binkley, S.N.; Wrighton, S.A. Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. Pharmacogenetics 1996, 6, 81-91.
122. Kubota, T.; Chiba, K.; Ishizaki, T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin. Pharmacol. Ther. 1996, 60, 661-666.
123. Klotz, U.; Schwab, M.; Treiber, G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin. Pharmacol. Toxicol. 2004, 95, 2-8.
124. Goldstein, J.A.; Ishizaki, T.; Chiba, K.; de Morais, S.M.; Bell, D.; Krahn, P.M.; Evans, D.A. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997, 7, 59-64.
125. Ishizaki, T.; Sohn, D.R.; Kobayashi, K.; Chiba, K.; Lee, K.H.; Shin, S.G.; Andersson, T.; Regardh, C.G.; Lou, Y.C.; Zhang, Y.; et al. Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther. Drug Monit. 1994, 16, 214-215.
126. Furuta, T.; Shirai, N.; Takashima, M.; Xiao, F.; Hanai, H.; Sugimura, H.; Ohashi, K.; Ishizaki, T.; Kaneko, E. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin. Pharmacol. Ther. 2001, 69, 158-168.
127. Furuta, T.; Ohashi, K.; Kamata, T.; Takashima, M.; Kosuge, K.; Kawasaki, T.; Hanai, H.; Kubota, T.; Ishizaki, T.; Kaneko, E. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann. Intern. Med. 1998, 129, 1027-1030.
128. Padol, S.; Yuan, Y.; Thabane, M.; Padol, I.T.; Hunt, R.H. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: A meta-analysis. Am. J. Gastroenterol. 2006, 101, 1467-1475.
129. Furuta, T.; Shirai, N.; Kodaira, M.; Sugimoto, M.; Nogaki, A.; Kuriyama, S.; Iwaizumi, M.; Yamade, M.; Terakawa, I.; Ohashi, K.; et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin. Pharmacol. Ther. 2007, 81, 521-528.